|
|
Post by kite on Dec 27, 2018 8:03:02 GMT -5
bit.ly/2BHc95ZDecember 27, 2018 08:00 ET | Source: MannKind WESTLAKE VILLAGE, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM (Eastern Time). Presenting from the Company will be its Chief Executive Officer, Michael Castagna. To participate in the live call by telephone, please dial (800) 263-0877 or (646) 828-8143 and use the participant passcode: 1338434. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com under News & Events. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 1338434#. A replay will also be available on MannKind's website for 14 days. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. Company Contact: Rose Alinaya SVP, Investor Relations 818.661.5000 ir@mannkindcorp.com
|
|
|
|
Post by boytroy88 on Dec 27, 2018 8:07:10 GMT -5
Darn, why so late? I was hoping that he'll hold it this year....i rather end the year with a bang than start off weakish then bang...but that's just me. January 4th can't come soon enough...the shorts are going to enjoy the next week. 😡 |
|
|
|
Post by mike0475 on Dec 27, 2018 8:14:07 GMT -5
Brazil final touches
|
|
|
|
Post by boytroy88 on Dec 27, 2018 8:15:15 GMT -5
|
|
|
|
Post by sayhey24 on Dec 27, 2018 8:19:08 GMT -5
This should be interesting and hopefully exciting. Either great news or a special voted to authorize new shares. I am planning for the latter and hoping Mike delivers on the former.
|
|
|
|
Post by rockstarrick on Dec 27, 2018 8:19:15 GMT -5
Darn, why so late? I was hoping that he'll hold it this year....i rather end the year with a bang than start off weakish then bang...but that's just me. January 4th can't come soon enough...the shorts are going to enjoy the next week. 😡 “the shorts are going to enjoy the next week”. or not ! the 4th is Friday, but typically bad news is released Friday at the market close, our call is at 9am EST. May not mean a thing,,, Time will tell |
|
|
|
Post by kite on Dec 27, 2018 8:21:06 GMT -5
Darn, why so late? I was hoping that he'll hold it this year....i rather end the year with a bang than start off weakish then bang...but that's just me. January 4th can't come soon enough...the shorts are going to enjoy the next week. 😡 Everyone is probably on vacation between Christmas and New Years |
|
|
|
Post by mnkdfann on Dec 27, 2018 9:24:59 GMT -5
Darn, why so late? I was hoping that he'll hold it this year....i rather end the year with a bang than start off weakish then bang...but that's just me. January 4th can't come soon enough...the shorts are going to enjoy the next week. 😡 Everyone is probably on vacation between Christmas and New Years  |
|
|
|
Post by brotherm1 on Dec 27, 2018 9:41:22 GMT -5
I’m cool with no conference or news this year. I’d rather wait until tax selling pressure ends
|
|
|
|
Post by #NoMoreNeedles on Dec 27, 2018 9:49:37 GMT -5
Only Mike will be presenting! I hope that this shelf offering of 26,666,667 common shares will turn out to be a 10% co-promotion partner buy-in  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 27, 2018 9:53:55 GMT -5
This should be interesting and hopefully exciting. Either great news or a special voted to authorize new shares. I am planning for the latter and hoping Mike delivers on the former. If they are asking for more shares, they better damn well include on the call specifics as to what the real strategic plan is and how they intend to execute. I have no desire to hear about impediments to making the company successful. He gets paid to overcome impediments. I don't want to hear about insurance either. I want results and despite what he has said on past calls, a big part of those results will be revealed every Friday via Rx data. I would want to know what has changed in terms of tools, claims etc that will allow for better Afrezza sales in the United States in 2019. I would want to know what new initiatives will be undertaken by the sales and marketing departments to allow for better Afrezza sales in the United States in 2019. I would want to know how much cash Mannkind will take in for 2019 due to non-United Therapeutics deals. I would want to know how much cash Mannkind will take in for 2019 from United Therapeutics. If Mike cannot speak to the above, I am not sure what the purpose of authorizing more shares would be. Sure, they can bring in more money but if the company keeps doing the same things, it will keep getting the same results. I need to know there is a viable plan that will improve Afrezza sales and / or allow for opportunities to transition the company to a bus dev entity for TS. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. If Mike doesn't speak to the above on the call and its only a feel good session to try and cool down the heat a bit, then its more of the same and the runway for the same old will run short. How many more years can Afrezza linger in the United States? Unless there is a complete pivot to a development company for TS, Afrezza must succeed in the US. Hopefully there is some great news on the call but I have seen this too many times so my optimism is muted. Afrezza remains the greatest advancement in diabetes care in many many decades. Its clinical performance and economic performance so far have a correlation of -1. |
|
|
|
Post by centralcoastinvestor on Dec 27, 2018 9:57:52 GMT -5
My opinion about this upcoming conference call is that is about the 2019 game plan. This recent money raise did not feel like it was part of the bigger plan but an adjustment to keep company on track with a larger strategy. My hope is that Mike lays out why 2019 will be a good year. I think we will hear about improved insurance coverage, progress on training and educating doctors, plans for continuing efforts at improving the SOC with ADA, further progress on the Technosphere pipeline etc.... Does the share price suck right now? YES! But we do want Mike focusing on the bigger game plan for building the company and reaching the hallowed ground of profitability.
|
|
|
|
Post by #NoMoreNeedles on Dec 27, 2018 9:59:48 GMT -5
Maybe you should email Mike and let him know your expectations?
|
|
|
|
Post by Clement on Dec 27, 2018 10:10:55 GMT -5
I’m cool with no conference or news this year. I’d rather wait until tax selling pressure ends Me, too, Bro. And let a little time pass. A couple of weeks after the shelf offering and into the new year, good news can be good news! |
|
|
|
Post by prcgorman2 on Dec 27, 2018 10:23:22 GMT -5
This should be interesting and hopefully exciting. Either great news or a special voted to authorize new shares. I am planning for the latter and hoping Mike delivers on the former. If they are asking for more shares, they better damn well include on the call specifics as to what the real strategic plan is and how they intend to execute. I have no desire to hear about impediments to making the company successful. He gets paid to overcome impediments. I don't want to hear about insurance either. I want results and despite what he has said on past calls, a big part of those results will be revealed every Friday via Rx data. I would want to know what has changed in terms of tools, claims etc that will allow for better Afrezza sales in the United States in 2019. I would want to know what new initiatives will be undertaken by the sales and marketing departments to allow for better Afrezza sales in the United States in 2019. I would want to know how much cash Mannkind will take in for 2019 due to non-United Therapeutics deals. I would want to know how much cash Mannkind will take in for 2019 from United Therapeutics. If Mike cannot speak to the above, I am not sure what the purpose of authorizing more shares would be. Sure, they can bring in more money but if the company keeps doing the same things, it will keep getting the same results. I need to know there is a viable plan that will improve Afrezza sales and / or allow for opportunities to transition the company to a bus dev entity for TS. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. If Mike doesn't speak to the above on the call and its only a feel good session to try and cool down the heat a bit, then its more of the same and the runway for the same old will run short. How many more years can Afrezza linger in the United States? Unless there is a complete pivot to a development company for TS, Afrezza must succeed in the US. Hopefully there is some great news on the call but I have seen this too many times so my optimism is muted. Afrezza remains the greatest advancement in diabetes care in many many decades. Its clinical performance and economic performance so far have a correlation of -1. "Hopefully there is some great news on the call but I have seen this too many times so my optimism is muted."
Wow, if that's your optimism, I'd sure hate to see what it's like when you rant.
|
|
